Results of Multivariate Analysis
| Variable . | Parameter Estimate . | OR . | P Value . |
|---|---|---|---|
| A. Risk of treatment interruption associated with thrombocytopenia | |||
| Total percentage of bone marrow irradiated | 1.42 | 4.1 | <.001 |
| Concurrent chemotherapy with high myelotoxicity potential | 3.82 | 45.5 | <.001 |
| Brain metastases | 2.0 | 7.3 | .01 |
| B. Risk of treatment interruption associated with neutropenia | |||
| Total percentage of bone marrow irradiated | 1.19 | 3.3 | <.001 |
| Concurrent chemotherapy with high myelotoxicity potential | 3.74 | 42.1 | <.001 |
| C. Risk of treatment interruption associated with both thrombocytopenia and neutropenia | |||
| Total percentage of bone marrow irradiated | 1.37 | 3.9 | <.001 |
| Concurrent chemotherapy with high myelotoxicity potential | 3.88 | 48.6 | <.001 |
| Variable . | Parameter Estimate . | OR . | P Value . |
|---|---|---|---|
| A. Risk of treatment interruption associated with thrombocytopenia | |||
| Total percentage of bone marrow irradiated | 1.42 | 4.1 | <.001 |
| Concurrent chemotherapy with high myelotoxicity potential | 3.82 | 45.5 | <.001 |
| Brain metastases | 2.0 | 7.3 | .01 |
| B. Risk of treatment interruption associated with neutropenia | |||
| Total percentage of bone marrow irradiated | 1.19 | 3.3 | <.001 |
| Concurrent chemotherapy with high myelotoxicity potential | 3.74 | 42.1 | <.001 |
| C. Risk of treatment interruption associated with both thrombocytopenia and neutropenia | |||
| Total percentage of bone marrow irradiated | 1.37 | 3.9 | <.001 |
| Concurrent chemotherapy with high myelotoxicity potential | 3.88 | 48.6 | <.001 |